Thyroid-receptor antibodies, immunoglubulin E and antinuclear antibodies in patients with Graves’ disease and their association with Graves’ orbitopathy and smoking habits

2021 ◽  
Author(s):  
Mariya Stoynova ◽  
Alexander Shinkov ◽  
Georgi Kirilov ◽  
Roussanka Kovatcheva
Keyword(s):  
Antinuclear Antibodies ◽  
Smoking Habits ◽  
Graves Disease ◽  
Graves Orbitopathy ◽  
Thyroid Receptor ◽  
Receptor Antibodies

scholarly journals High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease

2019 ◽  
Vol 104 (7) ◽  
pp. 2561-2568 ◽  
Author(s):  
George J Kahaly ◽  
Christian Wüster ◽  
Paul D Olivo ◽  
Tanja Diana
Keyword(s):  
De Novo ◽  
Graves Disease ◽  
Serum Dilution ◽  
Tertiary Referral Center ◽  
Thyrotropin Receptor Antibodies ◽  
High Dilutions ◽  
Graves Orbitopathy ◽  
Serial Serum ◽  
Receptor Antibodies

Abstract Context Serum TSH receptor autoantibody (TSH-R-Ab) is a biomarker of Graves disease (GD). Studies have shown that the levels of this TSH-R-Ab have clinical significance. Objective To differentiate between thyroidal GD only and Graves orbitopathy (GD + GO). Design Controlled, follow-up study. Setting Academic tertiary referral center for GD + GO. Subjects Sixty patients with GD, GD + GO, and controls. Intervention Serial serum dilution analyses with six automated, ELISA, and cell-based assays for TSH-R-Ab. Main Outcome Measure Differentiation among GD phenotypes. Results All undiluted samples of hyperthyroid-untreated GD patients were positive with the six assays but became negative at dilution 1:9 in four of six assays. In contrast, all undiluted samples of hyperthyroid-untreated GD + GO patients remained positive up to dilution 1:81, P < 0.001. At high dilutions 1:243, 1:729, 1:2187, and 1:6561, the rate of stimulating TSH-R-Ab positivity in the bioassay for GD + GO patients was 75%, 35%, 5%, and 0%, respectively (all P < 0.001). The five ELISA and/or automated assays confirmed this marked difference of anti-TSH-R-Ab detection between GD-only and GD + GO. In comparison, the baseline-undiluted samples of GD vs GD + GO showed an overlap in the ranges of TSH-R-Ab levels. Subsequent to 12-month methimazole treatment, samples from euthyroid GD + GO patients were still TSH-R-Ab positive at the high dilution of 1:243. In contrast, all GD samples were negative already at dilution 1:3. A GD patient with TSH-R-Ab positivity at dilution 1:729 developed de novo GO. Conclusions TSH-R-Ab titers, as determined by dilution analysis, significantly differentiate between GD and GD + GO.

scholarly journals Macular Rash, Thrombocytopenia, and Hyperbilirubinemia in a Preterm Infant

2019 ◽  
Vol 2019 ◽  
pp. 1-3
Author(s):  
Nurin Chatur ◽  
Marina Castro ◽  
Kin Fan Young Tai
Keyword(s):  
Preterm Infant ◽  
Early Identification ◽  
Congenital Infection ◽  
Rare Condition ◽  
Graves Disease ◽  
Macular Rash ◽  
Neonatal Hyperthyroidism ◽  
Thyroid Receptor ◽  
Maternal Thyroid ◽  
Receptor Antibodies

Neonatal hyperthyroidism is usually caused by the passage of maternal thyroid receptor antibodies. This relatively rare condition has various manifestations including cholestasis, prematurity, and cardiomegaly. We present a case of a preterm infant with neonatal Graves’ disease who presented with cholestasis, cardiomegaly, and a macularpapular rash that was thought to be suspicious for congenital infection. This case has been reported to illustrate lessons learnt for early identification of a neonate with Graves’ disease in order to expedite treatment.

Graves’ disease in a patient with Down syndrome: a shift from hyperthyroidism to hypothyroidism

2021 ◽  
Vol 14 (9) ◽  
pp. e242612
Author(s):  
Sara Todo Bom Costa ◽  
Vanessa Albino ◽  
Ana Peres ◽  
Patrícia Ferreira
Keyword(s):  
Down Syndrome ◽  
Rare Condition ◽  
Laboratory Evaluation ◽  
Graves Disease ◽  
Laboratory Studies ◽  
Thyroglobulin Antibodies ◽  
Increased Risk ◽  
Thyroid Receptor ◽  
Receptor Antibodies ◽  
New Onset

Down syndrome (DS) is associated with an increased risk of multisystemic dysfunction, namely endocrine abnormalities. Thyroid dysfunction is the most common endocrinological disorder, and it can manifest as either hypothyroidism or hyperthyroidism. A 16-year-old patient with DS developed hyperthyroidism after a lifetime of alternating between subclinical hypothyroidism and euthyroidism. He presented new onset weight loss, agitation and diarrhoea. Laboratory studies were compatible with hyperthyroidism. Thyroid receptor antibodies (TRAbs) were positive, antithyroid peroxidase antibodies and thyroglobulin antibodies were negative. Antithyroid medication (methimazole) was prescribed and, despite therapy adjustments, laboratory evaluation revealed new onset hypothyroidism with persistently positive TRAbs. He experienced weight gain and remained in a hypothyroid state even with withdrawal of methimazole and administration of levothyroxine. This case illustrates an example of Graves’ disease with coexisting stimulating and inhibiting TRAbs that led to a shift from hyperthyroidism to hypothyroidism, a rare condition in patients with DS.

Graves' ophthalmopathy and tobacco smoking

1993 ◽  
Vol 129 (2) ◽  
pp. 147-150 ◽  
Author(s):  
Leif Tallstedt ◽  
Göran Lundell ◽  
Adam Taube
Keyword(s):  
Risk Factor ◽  
Tobacco Smoking ◽  
Statistical Significance ◽  
Smoking Habits ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Graves Ophthalmopathy ◽  
Thyrotropin Receptor Antibodies ◽  
Receptor Antibodies

We have studied the smoking habits in a group of patients with hyperthyroidism caused by Graves' disease. One hundred and seventy-one patients were randomized to different forms of treatment for hyperthyroidism and the outcome of this study concerning Graves' ophthalmopathy has been described previously. There were 89 smokers (52%) and 82 non-smokers (48%). Among the smokers there were 32 patients (19%) who developed ophthalmopathy or deteriorated in an already present ophthalmopathy and 57 patients who did not (33%), whereas among the non-smokers, 14 (8%) had ophthalmopathy during the study and 68 (40%) did not (p =0.006). We could not obtain statistical significance when trying to demonstrate that smoking is a risk factor for the development of ophthalmopathy after treatment for hyperthyroidism. It was noted that smokers had higher pretreatment levels of thyrotropin-receptor antibodies (p = 0.027). In conclusion, these results support the previously described association between smoking and Graves' ophthalmopathy.

Anti-thyrotrophin receptor antibodies in Graves' disease as demonstrated directly by immunoprecipitation assay

1983 ◽  
Vol 102 (1) ◽  
pp. 49-56 ◽  
Author(s):  
Tjerk W. A de Bruin ◽  
Daan van der Heide ◽  
Maria C. Krol
Keyword(s):  
Binding Site ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Immunoprecipitation Assay ◽  
Receptor Complexes ◽  
Auto Antibody ◽  
Receptor Antibodies ◽  
Normal Controls

Abstract. An immunoprecipitation assay was developed to determine the presence of antibodies against human TSH1 receptors. With this assay we were able to demonstrate that in comparison with sera from normal controls, 24 out of 30 (80%) sera from patients with untreated Graves' disease could immunoprecipitate more [125I]TSH-TSH receptor complexes. In 9 assays, an average of 14.1 ± 3.7% (sd) of the [125I]TSH-TSH receptor complexes was immunoprecipitated by the 30 Graves' sera vs 9.8 ± 3.0% by the normal pool serum (n = 23) (P < 0.001) and 7.7 ± 2.8% by the 22 normal sera (P < 0.001). One serum of the 24 positive Graves' sera was studied in detail. The results suggest that this serum contained an anti-TSH receptor auto-antibody directed towards a different determinant on the TSH receptor than the TSH binding site.

The relationship between thyroid receptor antibody and anti mullerian hormone in Graves' disease

2019 ◽  
Author(s):  
Keziban Demir ◽  
Hakan Kursat ◽  
Sevde Yazici ◽  
Hamide Pişkinpaşa ◽  
Evin Bozkir ◽  
...  
Keyword(s):  
Graves Disease ◽  
Receptor Antibody ◽  
Thyroid Receptor ◽  
The Relationship
Sign in / Sign up

Export Citation Format

Share Document